CK0804 (investigational cell therapy for myelofibrosis)
Current understanding
To be populated as evidence accumulates.
Evidence log
- May 17, 20 — MPN | Tumor | CURE: Regulatory milestone (other): FDA granted Orphan Drug Designation to CK0804 cell therapy for myelofibrosis, facilitating its development pathway. (novelty: 3)
Open questions
Related
Contributing findings
MPN | Tumor | CURE
May 17, 2026
novelty 3
per-area 3
introduces